FrancophonIA/ELRC3.0 huggingface dataset:
English: In this case, where comparison is made between a product containing tartaric acid and another containing citric acid, and a formulation effect cannot be excluded due to the unknown impact of tartaric acid in the intestine, bioequivalence would have to be established through in vivo studies.
Estonian: Kui võrreldakse veterinaarravimit, mis sisaldab viinhapet, teise veterinaarravimiga, mis sisaldab sidrunhapet, ja kui ei saa välistada ravimvormist tulenevat mõju viinhappe teadmata toime tõttu sooles, tuleb bioekvivalentsus määrata in vivo uuringute alusel.
English: One possibility which could partially explain this difference was argued to be the fact that in the 1999 study, the litter was not removed, leading to a recirculation of doxycycline through the natural pecking behaviour of the chickens.
Estonian: Üks võimaliku selgitusena märkis müügiloa hoidja, et 1999. aasta uuringus ei eemaldatud kanade allapanu, mis viis doksütsükliini retsirkulatsioonile kanade organismis neile iseloomuliku allapanu nokkimise harjumuse tõttu.
English: Annex III
Estonian: LISA III
English: There are two authorised dosages: 10 mg/kg body weight for 4 consecutive days, for which the withdrawal period is 3 days, and 20 mg/kg body weight for 4 consecutive days for which the withdrawal period is 12 days.
Estonian: Veterinaarravimil on kaks heakskiidetud annustamisskeemi: 10 mg kehamassi kg kohta 4 järjestikusel päeval, mille korral on keeluaeg 3 päeva, ja 20 mg kehamassi kg kohta 4 järjestikusel päeval, mille korral on keeluaeg 12 päeva.
English: In this particular case, two residue studies from 1999 and 2011 using the actual formulation at the recommended dose were available.
Estonian: Käesoleval juhul on olemas kaks ravimijääkide vähenemise uuringut aastatest 1999 ja 2011, mis viidi läbi sama ravimi soovitatava annusega.
English: In order to address the concerns raised by the Netherlands, the MAH was requested to provide all available residue data for use of the product in chickens at the dose of 20 mg/kg body weight, together with an expert comment on the data and a justification for the meat withdrawal period in chickens.
Estonian: Madalmaade tõstatatud küsimuste hindamiseks paluti müügiloa hoidjal esitada kõik olemasolevad andmed ravimijääkide kohta veterinaarravimi kasutamisel kanadel annuses 20 mg kehamassi kg kohta koos eksperdi kommentaaride ja liha keeluaja põhjendusega.
English: Based on the results of the study a chicken meat withdrawal period of 5 days was supported using the CVMP accepted alternative approach.
Estonian: Nimetatud uuringu tulemused toetasid veterinaarravimite komitee tunnustatud alternatiivse lähenemisviisi alusel 5-päevast kanaliha keeluaega.
English: After reviewing the documentation submitted by the MAH, the CVMP concluded that there were not sufficient scientific grounds to revise its conclusions of 7 March 2013, which recommended a withdrawal period of 9 days for chicken for the dose of 20 mg/kg bw for 4 consecutive days.
Estonian: Pärast müügiloa hoidja esitatud dokumentidega tutvumist otsustas veterinaarravimite komitee, et puuduvad piisavad teaduslikud põhjendused, et taas läbi vaadata 7. märtsi 2013. aasta otsus, mille kohaselt soovitatakse kanadel annustamisskeemi 20 mg kehamassi kg kohta 4 järjestikusel päeval kasutamisel 9-päevast keeluaega.
English: Residue levels in the other tissues were below their respective MRLs from 4 days onwards.
Estonian: Teistes kudedes oli ravimijääkide sisaldus vastavast ravimijääkide piirnormist väiksem alates 4. päevast.
English: The CVMP considers that the MAH has not provided a sound justification as to why the findings from the 1999 residue depletion study should be ignored.
Estonian: Veterinaarravimite komitee otsustas, et müügiloa hoidja ei ole esitanud kaalukaid põhjendusi 1999. aasta ravimijääkide vähenemise uuringu tulemuste arvestamata jätmiseks.
English: Based on the results a chicken meat withdrawal period of 12 days was supported using the CVMP accepted statistical approach.
Estonian: Uuringu tulemused toetasid veterinaarravimite komitee tunnustatud statistilise lähenemisviisi alusel 12-päevast kanaliha keeluaega.
English: However, due to the legal basis of the variation application under consideration, the MAH had provided their own residue depletion data to support a withdrawal period and only these data must be considered.
Estonian: Samas on müügiloa hoidja tulenevalt muudatustaotluse õiguslikust alusest esitanud keeluaja toetuseks vaid enda korraldatud ravimijääkide vähendamise uuringute andmed.
English: Chickens: - Meat and offal: 9 days, following a dose rate of 20 mg/kg body weight for 4 days.
Estonian: Kanad: - Lihale ja söödavatele kudedele: 9 päeva pärast doosi 20 mg/kg kehamassi kohta kasutamist 4 päeval.
English: The marketing authorisation holder (MAH) Eurovet Animal Health BV, submitted an application for a type II variation to shorten the withdrawal period for chicken meat and offal at a dose rate of 20 mg/kg body weight for 4 consecutive days.
Estonian: Müügiloa hoidja Eurovet Animal Health BV esitas II tüüpi muudatuse taotluse, et vähendada kanade liha ja söödavate kudede keeluaega, kui kasutatakse annustamisskeemi 20 mg kehamassi kg kohta 4 järjestikusel päeval.
English: During the worksharing procedure a potential serious risk to human health was identified by the Netherlands regarding the appropriate withdrawal period for chicken meat and offal at a dose rate of 20 mg/kg body weight for 4 consecutive days.
Estonian: Tööjaotusmenetluse raames tõstatasid Madalmaad küsimuse võimalikust tõsisest ohust inimtervisele, mis tuleneb kanade liha ja söödavate kudede keeluajast, kui kasutatakse annustamisskeemi 20 mg kehamassi kg kohta 4 järjestikusel päeval.
English: The animals were given the correct dose and the product was administered appropriately and sufficient numbers of animals were used.
Estonian: Uuritavatele loomadele manustati nõuetekohaselt veterinaarravimi õige annus ja uuringusse oli kaasatud piisav arv katseloomi.
English: The CVMP has considered whether the differences in the conduct between the two latter residue depletion studies could be used to explain the disparity seen in the resulting withdrawal periods.
Estonian: Veterinaarravimite komitee arutas, kas uuringutulemuste alusel väljapakutud erinevaid keeluaegu saab põhjendada erinevustega nende kahe uuringu läbiviimisel.
English: Residue depletion data from a study conducted in 1993 have been provided.
Estonian: Müügiloa hoidja esitas ravimijääkide sisalduse vähenemise andmed 1993. aastal tehtud uuringust.
English: However, the apparent similarity of solubility within drinking water should not be understood as providing an argument for ruling out definitively a formulation effect due to the presence of tartaric acid.
Estonian: Siiski ei välista ilmne joogivees lahustuvuse sarnasus täielikult viinhappesisaldusest tuleneva ravimvormi võimalikku mõju.
English: Name
Estonian: Väljamõeldud nimetus
English: Doxycycline residue levels in muscle were below the muscle MRL from 5 days onwards.
Estonian: Alates 5. päevast oli doksütsükliini ravimijääkide sisaldus lihastes väiksem kui lihase ravimijääkide piirnorm (MRL).
English: Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names (see annex I) contains doxycycline hyclate as active ingredient.
Estonian: Soludox 500 mg/g ja sarnased nimetused (vt I lisa) on sigadele ja kanadele joogivees manustamiseks ette nähtud pulber, mis sisaldab toimeainena doksütsükliinhüklaati.
English: A well conducted residue depletion study using the actual product at the maximum dose for the maximum duration of treatment is considered the most appropriate way to generate data to determine a suitable withdrawal period for a product.
Estonian: Kõige kohasem lähenemisviis andmete kogumisel veterinaarravimi sobiva keeluaja määramiseks on hästi läbiviidud ravimijääkide vähenemise uuring, milles kasutatakse sama ravimi maksimaalset annust maksimaalse lubatava ravi kestuse korral.
English: As a result, the MAH proposes a meat withdrawal period of 6 days in chickens for Soludox 500 mg/g powder for use in drinking water for pigs and chickens when medicated at a dose of 20 mg/kg for 4 consecutive days.
Estonian: Sellest lähtuvalt on müügiloa hoidja välja pakkunud veterinaarravimi Soludox 500 mg/g pulbri (joogivees manustamiseks sigadele ja kanadele) keeluajaks 6 päeva, kui seda manustatakse annuses 20 mg kehamassi kg kohta 4 järjestikusel päeval.
English: The CVMP agreed that there is likely to be no significant difference in the solubility of the products on the market regardless of whether they contain tartaric acid or citric acid.
Estonian: Veterinaarravimite komitee möönis, et olenemata ravimite viin- või sidrunhappesisaldusest ei erine turustatavate veterinaarravimite lahustuvus oluliselt.
English: Residue depletion data from a study conducted in 2011 have been provided.
Estonian: Peale selle esitas müügiloa hoidja ravimijääkide vähenemise andmed 2011. aastal tehtud uuringust.
English: Amendments in the relevant sections of the summary of product characteristics, labelling and package leaflet
Estonian: RAVIMI OMADUSTE KOKKUVÕTE, TEKST SILDIL, PAKENDI INFOLEHT
English: Determination of the withdrawal period for chicken for the dose of 20 mg/kg body weight for 4 consecutive days
Estonian: Keeluaja määramine kanadel annustamisskeemiga 20 mg kehamassi kg kohta 4 järjestikusel päeval
English: Following the review of all the data provided, the CVMP considered that only the two later residues depletion studies (from 1999 and 2011) should be taken into account in order to establish a withdrawal period for chicken meat and offal at a dose rate of 20 mg/kg body weight for 4 consecutive days.
Estonian: Pärast kõigi esitatud andmetega tutvumist otsustas veterinaarravimite komitee, et kanade liha ja söödavate kudede keeluaja määramisel, kui kasutatakse annustamisskeemi 20 mg kehamassi kg kohta 4 järjestikusel päeval, võib arvestada üksnes kahte viimast (1999. ja 2011. aastast pärinevat) ravimijääkide vähenemise uuringut.
English: • the CVMP reviewed all available data submitted by the MAH, to support the withdrawal period for chicken meat and offal at a dose rate of 20 mg/kg body weight for 4 consecutive days;
Estonian: • veterinaarravimite komitee tutvus kõigi müügiloa hoidja esitatud olemasolevate andmetega, mis käsitlevad kanade liha ja söödavate kudede keeluaega, kui kasutatakse annustamisskeemi 20 mg kehamassi kg kohta 4 järjestikusel päeval;
English: The animals were given the correct dose and the product was administered appropriately.
Estonian: Uuritavatele loomadele manustati nõuetekohaselt veterinaarravimi õige annus.
English: Residue depletion data from a study conducted in 1999 have been provided.
Estonian: Müügiloa hoidja esitas ka ravimijääkide vähenemise andmed 1999. aastal tehtud uuringust.
English: However, it is not felt that this can be used to support the MAH's disregard for the 1999 study since birds of various weights and from different breeds will be treated with this product.
Estonian: Siiski ei ole need erinevused piisavad, et müügiloa hoidja võiks arvestamata jätta 1999. aasta uuringu tulemused, sest antud veterinaarravimiga ravitakse erinevas vanuses ja erineva kehamassiga kanu.
English: • the CVMP on the basis of the available residue depletion data considered that a withdrawal period of 9 days should be established for chicken meat and offal at a dose rate of 20 mg/kg body weight for 4 consecutive days; the CVMP recommended the granting of the variation to the terms of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/DC) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/DC) in accordance with the recommended changes in the relevant sections of the product information as set out in Annex III.
Estonian: soovitas veterinaarravimite komitee muuta veterinaarravimite Soludox 500 mg/g pulbri (joogivees manustamiseks sigadele ja kanadele (NL/V/0141/001/DC)) ja Soludox 500 mg/g pulbri (joogivees manustamiseks sigadele ja kanadele (UK/V/0349/001/DC)) müügilubade tingimusi kooskõlas ravimiteabe vastavate lõikude muudatustega, mis on esitatud III lisas.
English: Furthermore, the test product and Soludox 500 mg/g powder for use in drinking water for pigs and chickens have different composition.
Estonian: Pealegi on uuringus kasutatud veterinaarravim ja Soludox 500 mg/g pulber joogivees manustamiseks sigadele ja kanadele erineva koostisega.
English: Instead, a 9 days withdrawal period for chicken meat and offal is recommended following a dose rate of 20 mg/kg body weight for 4 consecutive days.
Estonian: Selle asemel soovitab veterinaarravimite komitee kasutada annustamisskeemiga 20 mg kehamassi kg kohta 4 järjestikusel päeval 9-päevast keeluaega.
English: Overall summary of the scientific evaluation of Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names (see annex I)
Estonian: Soludox 500 mg/g pulbri (joogivees manustamiseks sigadele ja kanadele) ning sarnaste nimetuste (vt I lisa) teadusliku hindamise üldkokkuvõte
English: It is not felt that this can be used to support the MAH's disregard for the 1999 study since birds of various breed, weight and age will be treated with this product.
Estonian: Need erinevused ei ole siiski piisavad, et müügiloa hoidja võiks arvestamata jätta 1999. aasta uuringu tulemused, sest kõnealuse veterinaarravimiga ravitakse erinevas vanuses ja erineva kehamassiga kanu.
English: The current CVMP guidance on the establishment of withdrawal periods had to be taken into account.
Estonian: Müügiloa hoidjal paluti andmete esitamisel lähtuda veterinaarravimite komitee kehtivatest keeluaja määramise juhistest.
English: Two residue depletion studies, one from 1999 and one from 2011, were considered by the CVMP as providing adequate data from which to derive a withdrawal period.
Estonian: Veterinaarravimite komitee arvamuse kohaselt on kahe ravimijääkide vähenemise uuringu (1999. ja 2011. aasta uuringu) andmed keeluaja määramiseks kohased.
English: Labelling:
Estonian: KEELUAJAD
English: There are few side effects, the most important one being infection.
Estonian: Kõrvalnähte on vähe ja neist kõige olulisem on infektsioon.
English: Further information on Skyrizi can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Skyrizi.
Estonian: Lisateave Skyrizi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Skyrizi.
English: What measures are being taken to ensure the safe and effective use of Skyrizi?
Estonian: Mis meetmed võetakse, et tagada Skyrizi ohutu ja efektiivne kasutamine?
English: The recommended dose is 150 mg (2 injections).
Estonian: Soovitatav annus on 150 mg (2 süsti).
English: The European Medicines Agency therefore decided that Skyrizi's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Skyrizi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Other information about Skyrizi
Estonian: Muu teave Skyrizi kohta
English: The first two doses of 150 mg are given 4 weeks apart while subsequent doses are given every 12 weeks.
Estonian: Esimesed kaks 150 mg annust manustatakse 4-nädalase vahega ja edasised annused iga 12 nädala järel.
English: After being trained, patients may inject Skyrizi themselves if the doctor considers it appropriate.
Estonian: Pärast asjakohase väljaõppe saamist tohivad patsiendid süstida Skyrizit ise, kui arst peab seda asjakohaseks.
English: What is Skyrizi and what is it used for?
Estonian: Mis on Skyrizi ja milleks seda kasutatakse?
English: Skyrizi must not be used in patients who have an ongoing infection that the doctor considers important.
Estonian: Skyrizit ei tohi kasutada patsiendid, kellel on aktiivne infektsioon, mida arst peab oluliseks.
English: As for all medicines, data on the use of Skyrizi are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Skyrizi kasutamise kohta pidevat järelevalvet.
English: The most common side effect with Skyrizi (which may affect more than 1 in 10 people) is upper respiratory infection (nose and throat infection).
Estonian: Skyrizi kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on ülemiste hingamisteede infektsioon (nina- ja neeluinfektsioon).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Skyrizi have been included in the summary of product characteristics and the package leaflet.
Estonian: Skyrizi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Skyrizi are carefully evaluated and any necessary action taken to protect patients.
Estonian: Skyrizi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: It is used in adults with moderate to severe disease and who require systemic treatment (treatment with medicines given by mouth or by injection).
Estonian: Ravimit kasutatakse täiskasvanutel, kel on mõõdukas kuni raske naastuline psoriaas ja kes vajavad süsteemset ravi (ravi suukaudsete või süstitavate ravimitega).
English: For more information about using Skyrizi, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Skyrizi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Improvements in symptoms were maintained after 52 weeks of treatment with Skyrizi.
Estonian: Sümptomite paranemine säilis pärast 52 ravinädalat Skyriziga.
English: What are the risks associated with Skyrizi?
Estonian: Mis riskid Skyriziga kaasnevad?
English: It is injected under the skin in an area that is clear of psoriasis, usually in the thighs or belly.
Estonian: Seda süstitakse naha alla kohta, kus ei ole psoriaatilist löövet, tavaliselt reie- või kõhulihasesse.
English: The doctor may decide to stop treatment if the condition does not improve after 16 weeks.
Estonian: Kui seisund ei ole 16 nädala pärast paranenud, võib arst otsustada ravi lõpetada.
English: In 4 main studies involving over 2,100 patients with moderate to severe disease who required systemic treatment, Skyrizi was more effective than placebo (a dummy treatment) and comparator medicines at improving symptoms.
Estonian: Neljas põhiuuringus, kus osales 2100 patsienti, kellel oli mõõdukas kuni raske naastuline psoriaas ja kes vajasid süsteemset ravi, oli Skyrizi sümptomite leevendamisel efektiivsem kui platseebo (näiv ravim) ja võrdlusravimid.
English: The active substance in Skyrizi, risankizumab, is a monoclonal antibody (a type of protein) that is designed to attach to interleukin 23 and block its activity.
Estonian: Skyrizi toimeaine risankizumab on monoklonaalne antikeha (teatud valk), mis seondub interleukiin-23ga ja blokeerib selle toime.
English: Studies have shown that Skyrizi is highly effective at clearing the skin and the positive effects are maintained with continued use.
Estonian: Uuringud on näidanud Skyrizi suurt efektiivsust nahalööbe ravimisel ning ravitoime püsimist pideval kasutusel.
English: How is Skyrizi used?
Estonian: Kuidas Skyrizit kasutatakse?
English: What benefits of Skyrizi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Skyrizi kasulikkus?
English: By blocking the action of interleukin 23, risankizumab reduces inflammation and symptoms associated with the disease.
Estonian: Interleukiin-23 toime blokeerimisega leevendab risankizumab põletikku ja haigussümptomeid.
English: In a second part of this study, some patients who first received Skyrizi were then switched to placebo after 28 weeks while others remained on Skyrizi.
Estonian: Uuringu teises osas anti mõnele varem Skyrizit saanud patsiendile 28 nädala pärast platseebot, samal ajal kui teised jätkasid Skyrizi võtmist.
English: Interleukin 23 is a messenger molecule of the body's immune system (the body's natural defences) and is involved in causing inflammation that is linked to the formation of plaque psoriasis.
Estonian: Interleukiin-23 on immuunsüsteemi (organismi loodusliku kaitsemehhanismi) virgatsaine, mis osaleb naastulise psoriaasi tekkega seostatavates põletikuprotsessides.
English: How does Skyrizi work?
Estonian: Kuidas Skyrizi toimib?
English: Skyrizi is available in pre-filled syringes.
Estonian: Skyrizit turustatakse eeltäidetud süstaldes.
English: At week 52, more patients who remained on Skyrizi had had clear or almost clear skin than those who were switched to placebo.
Estonian: 52. nädalal oli nahk puhas või peaaegu puhas rohkematel Skyriziga jätkanud patsientidel kui nendel, kes hakkasid võtma platseebot.
English: In the first two studies in a total of 997 patients, after 16 weeks of treatment around 75% of patients receiving Skyrizi had a reduction of at least 90% in PASI scores (a measure of how severe and widespread the skin lesions are), compared with around 45% of those receiving ustekinumab and around 4% of those receiving placebo.
Estonian: Esimeses kahes uuringus, kus osales kokku 997 patsienti, oli patsiente, kellel vähenes psoriaasi ulatuse ja raskuse indeksi (nahakahjustuste raskusastme ja haaratud nahapindala mõõt, PASI) skoor vähemalt 90%, Skyziri rühmas ligikaudu 75%, ustekinumaabirühmas ligikaudu 45% ja platseeborühmas ligikaudu 4%.
English: An overview of Skyrizi and why it is authorised in the EU
Estonian: Ülevaade ravimist Skyrizi ja ELis müügiloa väljastamise põhjendus
English: In the third study involving 605 patients, after 16 weeks of treatment 72% of patients receiving Skyrizi had a reduction of at least 90% in PASI scores, compared with 47% of those receiving adalimumab.
Estonian: Kolmandas uuringus, kus osales 605 patsienti, oli patsiente, kellel vähenes 16 ravinädala järel PASI skoor vähemalt 90%, Skyrizi rühmas 72% ja adalimumaabirühmas 47%.
English: Skyrizi can only be obtained with a prescription and should be used under the supervision of a doctor experienced in diagnosing and treating plaque psoriasis.
Estonian: Seda peab kasutama naastulise psoriaasi diagnostikas ja ravis kogenud arsti järelevalve all.
English: Skyrizi contains the active substance risankizumab.
Estonian: Skyrizi sisaldab toimeainena risankizumabi.
English: Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin.
Estonian: Skyrizi on ravim, mida kasutatakse naastulise psoriaasi raviks.
English: In addition, around 86% of patients receiving Skyrizi had clear or almost clear skin, compared with around 62% of those receiving ustekinumab and around 6% of those receiving placebo.
Estonian: Puhta või peaaegu puhta nahaga patsiente oli Skyrizi rühmas ligikaudu 86%, ustekinumaabirühmas ligikaudu 62% ja platseeborühmas ligikaudu 6%.
English: Finally, in the fourth study involving 507 patients, after 16 weeks of treatment 73% of patients receiving Skyrizi had a reduction of at least 90% in PASI scores, compared with 2% of those receiving placebo.
Estonian: Neljandas, 507 patsiendiga uuringus, oli patsiente, kellel vähenes 16 ravinädala järel PASI skoor vähemalt 90%, Skyrizi rühmas 73% ja platseeborühmas 2%.
English: In addition, 84% of patients receiving Skyrizi had clear or almost clear skin, compared with 60% of those receiving adalimumab.
Estonian: Puhta või peaaegu puhta nahaga patsiente oli Skyrizi rühmas 84% ja adalimumaabirühmas 60%.
English: Around 84% of patients receiving Skyrizi had clear or almost clear skin, compared with around 7% of those receiving placebo.
Estonian: Puhta või peaaegu puhta nahaga patsiente oli Skyrizi rühmas ligikaudu 84% ja platseeborühmas ligikaudu 7%.
English: Why is Skyrizi authorised in the EU?
Estonian: ELis Skyrizile väljastatud müügiloa põhjendus
English: (Invented) name Strength
Estonian: (Väljamõeldud) nimetus
English: Pharmaceutical form
Estonian: Ravimvorm Manustamistee Sisepakendi iseloomustus
English: ATC vet code: QI07AD04.
Estonian: ATCvet kood: QI07AD04.
English: If protection against rabies is required:
Estonian: Kui on vaja kaitset marutaudi vastu
English: This can be painful, warm or reddened.
Estonian: See võib olla valulik, soe või punetav.